Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Resistance to Antibody-Drug Conjugates.

García-Alonso S, Ocaña A, Pandiella A.

Cancer Res. 2018 Apr 13. doi: 10.1158/0008-5472.CAN-17-3671. [Epub ahead of print] Review.

PMID:
29653942
2.

Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.

Shepshelovich D, Tibau A, Goldvaser H, Molto C, Ocana A, Seruga B, Amir E.

J Clin Oncol. 2018 Apr 11:JCO2017775593. doi: 10.1200/JCO.2017.77.5593. [Epub ahead of print]

PMID:
29641296
3.

Selection of tawny owl (Strix aluco) flight feather shaft for biomonitoring As, Cd and Pb pollution.

Seoane RG, Río ZV, Ocaña AC, Escribano JÁF, Viñas JRA.

Environ Sci Pollut Res Int. 2018 Apr 7. doi: 10.1007/s11356-018-1477-5. [Epub ahead of print]

PMID:
29627961
4.

Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer.

Tibau A, Anguera G, Andrés-Pretel F, Templeton AJ, Seruga B, Barnadas A, Amir E, Ocana A.

Oncotarget. 2018 Feb 28;9(19):15061-15067. doi: 10.18632/oncotarget.24589. eCollection 2018 Mar 13.

5.

Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.

Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B, Pandiella A, Galán-Moya EM, Ocaña A.

Cancer Med. 2018 Mar 25. doi: 10.1002/cam4.1406. [Epub ahead of print]

6.

Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.

Ethier JL, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M, Sánchez-Aragó M, Carrasco E, Caballero R, Amir E, Martin M.

Eur J Cancer. 2018 May;94:199-205. doi: 10.1016/j.ejca.2018.02.018. Epub 2018 Mar 21.

PMID:
29573665
7.

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.

Goldvaser H, Majeed H, Ribnikar D, Šeruga B, Ocaña A, Cescon DW, Amir E.

Breast Cancer Res Treat. 2018 Feb 8. doi: 10.1007/s10549-018-4710-5. [Epub ahead of print] Review.

PMID:
29423899
8.

Gas phase kinetics of the OH + CH3CH2OH reaction at temperatures of the interstellar medium (T = 21-107 K).

Ocaña AJ, Blázquez S, Ballesteros B, Canosa A, Antiñolo M, Albaladejo J, Jiménez E.

Phys Chem Chem Phys. 2018 Feb 21;20(8):5865-5873. doi: 10.1039/c7cp07868d.

PMID:
29417104
9.

Transcriptome evolution from breast epithelial cells to basal-like tumors.

Santpere G, Alcaráz-Sanabria A, Corrales-Sánchez V, Pandiella A, Győrffy B, Ocaña A.

Oncotarget. 2017 Dec 8;9(1):453-463. doi: 10.18632/oncotarget.23065. eCollection 2018 Jan 2.

10.

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis.

Barua R, Templeton AJ, Seruga B, Ocana A, Amir E, Ethier JL.

Clin Oncol (R Coll Radiol). 2018 Apr;30(4):215-224. doi: 10.1016/j.clon.2018.01.003. Epub 2018 Feb 12.

PMID:
29395413
11.

Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.

Nuncia-Cantarero M, Martinez-Canales S, Andrés-Pretel F, Santpere G, Ocaña A, Galan-Moya EM.

Breast Cancer Res Treat. 2018 Apr;168(3):613-623. doi: 10.1007/s10549-017-4652-3. Epub 2018 Jan 12.

12.

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

Tibau A, Molto C, Ocana A, Templeton AJ, Del Carpio LP, Del Paggio JC, Barnadas A, Booth CM, Amir E.

J Natl Cancer Inst. 2017 Dec 13. doi: 10.1093/jnci/djx232. [Epub ahead of print]

PMID:
29244173
13.

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Perez-Peña J, Corrales-Sánchez V, Amir E, Pandiella A, Ocana A.

Sci Rep. 2017 Dec 13;7(1):17530. doi: 10.1038/s41598-017-17836-7.

14.

Reporting of Randomized Trials in Common Cancers in the Lay Media.

Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir E.

Oncology. 2018;94(2):65-71. doi: 10.1159/000484630. Epub 2017 Nov 18.

PMID:
29151109
15.

Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.

Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE.

Cancer Treat Rev. 2018 Jan;62:1-8. doi: 10.1016/j.ctrv.2017.10.008. Epub 2017 Oct 31. Review.

PMID:
29126017
16.

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.

Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, Trigo JM, Muñoz M, Pandiella A, Diego NG, Bezares S, Caballero R, Carrasco E, Urruticoechea A.

Oncotarget. 2017 Apr 14;8(42):73144-73153. doi: 10.18632/oncotarget.17113. eCollection 2017 Sep 22.

17.

BET inhibitors as novel therapeutic agents in breast cancer.

Ocaña A, Nieto-Jiménez C, Pandiella A.

Oncotarget. 2017 Aug 1;8(41):71285-71291. doi: 10.18632/oncotarget.19744. eCollection 2017 Sep 19. Review.

18.

Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.

Orive-Ramos A, Seoane S, Ocaña A, Pandiella A, Montero JC.

Mol Oncol. 2017 Dec;11(12):1788-1805. doi: 10.1002/1878-0261.12145. Epub 2017 Oct 31.

19.

Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.

Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, Amir E.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx141. Review.

PMID:
28922781
20.

Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis.

Goldvaser H, AlGorashi I, Ribnikar D, Seruga B, Templeton AJ, Ocana A, Amir E.

Cancer Treat Rev. 2017 Nov;60:53-59. doi: 10.1016/j.ctrv.2017.08.008. Epub 2017 Aug 24. Review.

PMID:
28881223
21.

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.

Alcaraz-Sanabria A, Nieto-Jiménez C, Corrales-Sánchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC, Burgos M, Llopis J, Galán-Moya EM, Pandiella A, Ocaña A.

Mol Cancer Ther. 2017 Nov;16(11):2552-2562. doi: 10.1158/1535-7163.MCT-17-0223. Epub 2017 Aug 28.

PMID:
28847989
22.

Neutrophils in cancer: prognostic role and therapeutic strategies.

Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ.

Mol Cancer. 2017 Aug 15;16(1):137. doi: 10.1186/s12943-017-0707-7. Review.

23.

Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer.

Goldvaser H, Ribnikar D, Fazelzad R, Seruga B, Templeton AJ, Ocana A, Amir E.

Cancer Treat Rev. 2017 Sep;59:46-53. doi: 10.1016/j.ctrv.2017.06.007. Epub 2017 Jul 11. Review.

PMID:
28734183
24.

Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.

Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, Nadal-Serrano M, Arribas J, Ocaña A, Pandiella A.

Cancer Res. 2017 Sep 1;77(17):4639-4651. doi: 10.1158/0008-5472.CAN-16-3127. Epub 2017 Jul 7.

PMID:
28687619
25.

Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression.

Adam R, Díez-González L, Ocaña A, Šeruga B, Amir E, Templeton AJ.

Exp Mol Pathol. 2017 Jun;102(3):455-474. doi: 10.1016/j.yexmp.2017.05.010. Epub 2017 May 12.

PMID:
28506770
26.

Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.

Martínez-Canales S, Cifuentes F, López De Rodas Gregorio M, Serrano-Oviedo L, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocaña A.

PLoS One. 2017 May 4;12(5):e0175128. doi: 10.1371/journal.pone.0175128. eCollection 2017.

27.

Atmospheric degradation of 2-chloroethyl vinyl ether, allyl ether and allyl ethyl ether: Kinetics with OH radicals and UV photochemistry.

Antiñolo M, Ocaña AJ, Aranguren JP, Lane SI, Albaladejo J, Jiménez E.

Chemosphere. 2017 Aug;181:232-240. doi: 10.1016/j.chemosphere.2017.04.053. Epub 2017 Apr 18.

PMID:
28441613
28.

Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.

Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, Ocana A.

Cancer Treat Rev. 2017 May;56:1-7. doi: 10.1016/j.ctrv.2017.03.011. Epub 2017 Apr 9. Review.

PMID:
28437678
29.

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 28;8(13):21733-21740. doi: 10.18632/oncotarget.15562.

30.

Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs.

Tibau A, Díez-González L, Navarro B, Galán-Moya EM, Templeton AJ, Seruga B, Pandiella A, Amir E, Ocana A.

Mol Diagn Ther. 2017 Jun;21(3):337-343. doi: 10.1007/s40291-017-0267-y.

PMID:
28247182
31.

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.

Ocana A, Pandiella A.

Oncotarget. 2017 Mar 28;8(13):22218-22234. doi: 10.18632/oncotarget.14731. Review.

32.

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Nieto-Jiménez C, Alcaraz-Sanabria A, Pérez-Peña J, Corrales-Sánchez V, Serrano-Heras G, Galán-Moya EM, Serrano-Oviedo L, Montero JC, Burgos M, Llopis J, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 21;8(12):19478-19490. doi: 10.18632/oncotarget.14465.

33.

Relevance of randomised controlled trials in oncology.

Tannock IF, Amir E, Booth CM, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F.

Lancet Oncol. 2016 Dec;17(12):e560-e567. doi: 10.1016/S1470-2045(16)30572-1. Review.

PMID:
27924754
34.

Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.

Niraula S, Ocana A.

Cancer Treat Rev. 2016 Nov;50:168-174. doi: 10.1016/j.ctrv.2016.09.011. Epub 2016 Sep 20. Review.

PMID:
27693931
35.

Honorary and ghost authorship in reports of randomised clinical trials in oncology.

Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Templeton AJ, Seruga B, Amir E, Tannock IF.

Eur J Cancer. 2016 Oct;66:1-8. doi: 10.1016/j.ejca.2016.06.023. Epub 2016 Aug 6.

PMID:
27500368
36.

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.

Nieto-Jiménez C, Alcaraz-Sanabria A, Páez R, Pérez-Peña J, Corrales-Sánchez V, Pandiella A, Ocaña A.

Oncotarget. 2016 Jul 28;8(38):62834-62841. doi: 10.18632/oncotarget.10886. eCollection 2017 Sep 8.

37.

Targeting the EGF/HER Ligand-Receptor System in Cancer.

Esparís-Ogando A, Montero JC, Arribas J, Ocaña A, Pandiella A.

Curr Pharm Des. 2016;22(39):5887-5898. Review.

PMID:
27426127
38.

Under-reporting of harm in clinical trials.

Seruga B, Templeton AJ, Badillo FE, Ocana A, Amir E, Tannock IF.

Lancet Oncol. 2016 May;17(5):e209-19. doi: 10.1016/S1470-2045(16)00152-2. Epub 2016 Apr 27. Review.

PMID:
27301048
39.

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.

Pérez-Peña J, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Pandiella A, Ocaña A.

Mol Cancer Ther. 2016 Aug;15(8):1823-33. doi: 10.1158/1535-7163.MCT-16-0004. Epub 2016 Jun 2.

40.

Toward Value-Based Pricing to Boost Cancer Research and Innovation.

Ocana A, Amir E, Tannock IF.

Cancer Res. 2016 Jun 1;76(11):3127-9. doi: 10.1158/0008-5472.CAN-15-3179. Epub 2016 May 16.

41.

Bias in reporting of randomised clinical trials in oncology.

Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF.

Eur J Cancer. 2016 Jul;61:29-35. doi: 10.1016/j.ejca.2016.03.066. Epub 2016 May 3.

PMID:
27151552
42.

Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.

Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, Srikanthan A, Pandiella A, Amir E, Ocana A.

PLoS One. 2016 May 5;11(5):e0154789. doi: 10.1371/journal.pone.0154789. eCollection 2016. Review.

43.

Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.

Ocaña A, Díez-González L, Esparís-Ogando A, Montero JC, Amir E, Pandiella A.

Oncotarget. 2016 Jul 19;7(29):45042-45051. doi: 10.18632/oncotarget.8648.

44.

In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.

Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, Sánchez-Corrales V, Nieto-Jiménez C, Templeton AJ, Seruga B, Pandiella A, Amir E.

Oncotarget. 2016 Apr 19;7(16):22865-72. doi: 10.18632/oncotarget.8118.

45.

Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.

Tibau A, Ocana A, Anguera G, Seruga B, Templeton AJ, Barnadas A, Amir E.

JAMA Oncol. 2016 Jun 1;2(6):744-50. doi: 10.1001/jamaoncol.2015.6479.

PMID:
26940233
46.

Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer.

Ocaña A, Pérez-Peña J, Díez-González L, Sánchez-Corrales V, Templeton A, Seruga B, Amir E, Pandiella A.

Breast Cancer Res Treat. 2016 Feb;156(1):1-8. doi: 10.1007/s10549-016-3720-4. Epub 2016 Feb 20.

PMID:
26897635
47.

Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.

Zist A, Amir E, Ocana AF, Seruga B.

Radiol Oncol. 2015 Nov 27;49(4):402-8. doi: 10.1515/raon-2015-0038. eCollection 2015 Dec.

48.

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies.

Srikanthan A, Vera-Badillo F, Ethier J, Goldstein R, Templeton AJ, Ocana A, Seruga B, Amir E.

Cancer Treat Rev. 2016 Feb;43:67-73. doi: 10.1016/j.ctrv.2015.12.006. Epub 2015 Dec 31. Review.

PMID:
26827694
49.

Expert Opinion and Recommendations for the Management of Attention-Deficit/Hyperactivity Disorder in Correctional Facilities.

Scott DA, Gignac M, Kronfli RN, Ocana A, Lorberg GW.

J Correct Health Care. 2016 Jan;22(1):46-61. doi: 10.1177/1078345815618392.

PMID:
26672119
50.

Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development.

Ocana A, Pandiella A.

Curr Cancer Drug Targets. 2017;17(1):48-52. Review.

PMID:
26648484

Supplemental Content

Support Center